Royalty Pharma deal gives Revolution access to $2 billion in financing

24 June 2025

Revolution Medicines (Nasdaq: RVMD), a Californian oncology specialist developing targeted therapies for RAS-addicted cancers, has partnered with Royalty Pharma (Nasdaq: RPRX) on $2 billion in flexible funding to support the former company’s independent global development and commercialization strategy and operations.

Full strategic and executional control of product development and commercialization is retained by Revolution for its portfolio of RAS(ON) inhibitors in the USA and internationally, enabling the company to direct its assets, capabilities and momentum toward establishing new global standards of care and creating value for shareholders.

A new funding paradigm for highly innovative biotech companies

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK